Status and phase
Conditions
Treatments
About
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma.
Full description
This study is a Phase IIa, randomized, placebo-controlled, double-blind, 2-way crossover, 2-center (conducted in EU; The Netherlands) study in male and female subjects with stable, mild HDM-allergic asthma. The study will consist of two identical study periods of 12 treatment days each, separated by a washout period of at least 3 weeks (and no more than 7 weeks). Approximately 36 eligible subjects will be enrolled, to yield 32 evaluable subjects who will be treated with both FP-025 (400 mg BID) or matching placebo in a cross-over design from the evening of Day 1 till the morning of Day 12 (22 doses per study period in total).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
The following criteria must be met by all subjects considered for study participation:
Females or males, between 18 and 55 years of age at Screening, inclusive, on the day of signing the Informed Consent Form (ICF).
Apart from a clinically stable asthma and HDM-allergy, subjects should be generally healthy with no history of a clinically relevant medical condition that in the opinion of the investigator might interfere with successful study conduct and no clinically relevant abnormalities on medical history, physical exam, vital signs, laboratory parameters or ECG at Screening.
Subject has a BMI ≥ 18.0 kg/m2 and ≤ 32.0 kg/m2 (and weighs ≥50 kg).
Subjects have been diagnosed with asthma cf GINA guidelines.
Subjects should have established allergy for HDM (serum HDM-specific IgE or positive SPT at Screening or documented within 1 year pre-screening).
No severe exacerbation of asthma within past 1 year requiring hospital admission and/or treatment with oral corticosteroids; no (never) intensive care admissions for asthma or intubation).
FEV1 should be ≥70% of predicted on Screening Day 2.
On Screening Day 2, PC20FEV1(Meth) should be <16 mg/mL if methacholine chloride is used (or adjusted by a factor of 1.2 if methacholine bromide is used).
Baseline blood eosinophils should be ≥150 cells/μL at Screening or documented within 3 months before Screening Day 1.
Subjects should have a documented airway late response to inhaled HDM on Screening Day 3.
Subjects of childbearing potential must be willing to use adequate contraception (double-barrier) or must refrain from intercourse.
Female subjects of non-childbearing potential must have had
≥ 12 months of spontaneous amenorrhea (with folliclestimulating hormone [FSH] ≥ 30 mIU/mL). Surgically sterile women are defined as those who have had a hysterectomy, bilateral ovariectomy (for 'benign' reasons), or bilateral tubal ligation.
All female subjects should have a negative pregnancy test at Screening and on Day -1.
Negative alcohol breath test on Screening Day 1 and Day -1.
Negative cotinine test on Screening Day 1 and Day -1.
Negative urine drug screen for recreational and other drugs on Screening Day 1 and Day -1.
Subjects are non-smokers. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to Screening Day 1. Number of years smoked x number of packs per day should be <5 pack years.
Subject should be willing and able to perform the lung function tests and other study-related procedures and comply with study protocol requirements.
Subject should provide a signed and dated informed consent.
Exclusion criteria
Subjects will be excluded if they meet any of the following criteria:
Primary purpose
Allocation
Interventional model
Masking
27 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal